Research Grade Inotuzumabc (DHD38502)
Research Grade Inotuzumabc (DHD38502) Basic information
- Product Name:
- Research Grade Inotuzumabc (DHD38502)
- Synonyms:
-
- Research Grade Inotuzumabc (DHD38502)
- Inotuzumab (anti-CD22)
- CAS:
- 1660159-36-3
- MW:
- 0
- Mol File:
- Mol File
Research Grade Inotuzumabc (DHD38502) Chemical Properties
- form
- Liquid
- color
- Colorless to light yellow
Research Grade Inotuzumabc (DHD38502) Usage And Synthesis
Uses
Inotuzumab (Humanized Anti-CD22 Recombinant Antibody) is a humanized IgG4, κ antibody that targets human CD22. Inotuzumab can be linked to a toxic agent ozogamicin as an antibody-drug conjugate (ADC). Inotuzumab can be used for the research of acute lymphoblastic leukemia and non-Hodgkin lymphoma[1][2][3][4].
in vivo
Inotuzumab ozogamicin (100 μg/kg, i.p., twice a week for 2 weeks) combined with Venetoclax (HY-15531), Dexamethasone (HY-14648) induces long-term survival in murine patient-derived xenograft (PDX) models[3].
Inotuzumab (0.27, 3.2 mg/kg, i.p., a single dose for 400 h) inhibits tumor growth in mouse xenograft models[4].
| Animal Model: | Mouse xenograft models[4]. |
| Dosage: | 0.27, 3.2 mg/kg |
| Administration: | i.p., a single dose for 400 h |
| Result: | Decreased the tumor volume in mouse xenograft models. |
References
[1] Aujla A, et al. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Biomark Res. 2019 Apr 11;7:9. DOI:10.1186/s40364-019-0160-4
[2] Wynne J, et al. Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia. Blood Adv. 2019 Jan 8;3(1):96-104. DOI:10.1182/bloodadvances.2018026211
[3] Kirchhoff H, et al. Venetoclax and dexamethasone synergize with inotuzumab ozogamicin-induced DNA damage signaling in B-lineage ALL. Blood. 2021 May 13;137(19):2657-2661. DOI:10.1182/blood.2020008544
[4] Betts AM, et al. Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin. AAPS J. 2016 Sep;18(5):1101-1116. DOI:10.1208/s12248-016-9929-7
Research Grade Inotuzumabc (DHD38502)Supplier
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Tel
- 15002134094
- marketing@targetmol.cn
- Tel
- 400-821-026
- Sales@sangon.com